NVS
Novartis AG
$158.87
장중 · Vol 134.0K · 52주 $121.57–$170.46 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $151.87 · Aug 31, 2026
NVS 가격 추세
종가
$151.87
시가
$152.60
고가
$152.66
저가
$151.68
30초 브리핑
NVS 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 76%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 15.5배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-10-27
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
NVS 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Lichtstrasse 35 · Basel, Switzerland · 직원 75,267명
시가총액
$289.02B
Trailing P/E
23.3
최근 12개월 이익 기준
Forward P/E
15.5
이익 증가 기대 반영
EPS (TTM)
$6.61
배당 수익률
3.08%
배당성향
71.6%
베타
0.49
시장보다 방어적
ROE
30.3%
P/B
6.96
EV/EBITDA
14.5
52주 범위
$121.57 – $170.46
현재 위치 76%
거래량
1.08M
20일 평균 1.11M · 1.0배
애널리스트 의견
매수 42%
총 12명 · 0m
DITM LEAPS Analysis
NVS 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVS271217C00100000 | 12/17/27 · 1.3Y | $100.00 | $61.30 | 2.2x | 0.8693 | 15.1% | 5.87% | 50.05% | 1 | 72.41 | |
| NVS271217C00115000 | 12/17/27 · 1.3Y | $115.00 | $48.75 | 2.5x | 0.8170 | 24.0% | 5.13% | 46.33% | 5 | 65.68 | |
| NVS271217C00125000 | 12/17/27 · 1.3Y | $125.00 | $41.20 | 2.9x | 0.7760 | 34.3% | 8.25% | 43.91% | 3 | 56.11 |
재무제표
NVS 연간 손익·현금흐름·재무상태
매출 성장률
+9.6%
최근 연간 YoY
EPS 성장률
+21.8%
최근 연간 YoY
영업이익률
31.1%
최근 연간
FCF 마진
26.9%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $56.67B+9.6% | $51.72B+10.8% | $46.66B+7.4% | $43.46B |
| 매출총이익 | $42.98B+10.5% | $38.90B+13.8% | $34.19B+7.2% | $31.88B |
| 영업이익 | $17.64B+21.3% | $14.54B+48.9% | $9.77B+22.9% | $7.95B |
| 순이익 | $13.98B+17.1% | $11.94B-19.6% | $14.85B+113.5% | $6.96B |
| 희석 EPS | $7.15+21.8% | $5.87-17.3% | $7.10+124.0% | $3.17 |
| EBITDA | $22.82B+10.2% | $20.71B+13.5% | $18.25B+24.3% | $14.68B |
| 영업현금흐름 | $19.14B+8.7% | $17.62B+21.9% | $14.46B+1.6% | $14.24B |
| 잉여현금흐름 | $15.24B+10.4% | $13.80B+17.9% | $11.71B-2.4% | $12.00B |
| 총자산 | $110.95B+8.5% | $102.25B+2.3% | $99.94B-14.9% | $117.45B |
| 총부채 | $35.38B+13.2% | $31.26B+18.6% | $26.35B-5.6% | $27.91B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
NVS 실적·배당 일정
매출 하단
$14.33B
EPS 하단
$2.20
매출 상단
$14.86B
배당 지급일
2026-03-16
169일 전
실적 발표일
2026-10-27
D-56
EPS 상단
$2.26
매출 컨센서스
$14.65B
EPS 컨센서스
$2.23
배당락일
2026-03-11
174일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Mar 11, 2026 | $4.7730 |
| Mar 12, 2025 | $3.9940 |
| Mar 7, 2024 | $3.7400 |
| Mar 9, 2023 | $3.4690 |
| Mar 8, 2022 | $3.3570 |
| Mar 4, 2021 | $3.3780 |
| Mar 3, 2020 | $3.0420 |
| Mar 4, 2019 | $2.5672 |
뉴스
NVS 관련 최신 기사
일반Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
The Wall Street Journal · Sep 1, 2026
- 일반
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
BioPharma Dive · Aug 31, 2026
일반Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Zacks · Aug 27, 2026
규제·법률FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks · Aug 27, 2026
- 제품·기술
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.
Stocktwits · Aug 25, 2026
주주환원VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.
MarketBeat · Aug 23, 2026
실적Sustainable Development ETF (SDG) Touches New 52-Week High
SDG hits a 52-week high as strong earnings from top holdings and institutional ESG inflows fuel momentum, with alpha signaling more gains.
Zacks · Aug 21, 2026
제품·기술Novartis (SWX:NOVN) Stock Could Trade Below Fair Value Despite Entresto Patent Win
Novartis stock has delivered a 92.5% return over the past 5 years, which raises a clear valuation question for investors now that market multiples still screen it as undervalued while broader checks point to a more mixed picture. Over 5 years, Novartis has returned 92.5%, which places recent share performance firmly in focus when judging whether current pricing already reflects much of the progress. Upcoming cardiovascular data at the 2026 ESC Congress and the recent UK court win protecting...
Simply Wall St. · Aug 20, 2026
- 제품·기술
Novartis (SWX:NOVN) Trades At A 30% Premium After ESC Abstract Update
Novartis (SWX:NOVN) is drawing fresh attention after announcing plans to present data from 10 cardiovascular abstracts at the 2026 European Society of Cardiology Congress, spanning LDL cholesterol, atrial fibrillation and heart failure. See our latest analysis for Novartis. Alongside the upcoming ESC data, Novartis has seen firm price momentum, with a 1-month share price return of 3.27% and a year to date share price return of 17.16%. The 5-year total shareholder return of 92.48% points to...
Simply Wall St. · Aug 20, 2026
- 일반
Novartis (SWX:NOVN) Lines Up Pivotal Cardiovascular Data For ESC 2026
Novartis (SWX:NOVN) plans to present late breaking data from multiple pivotal cardiovascular studies at the 2026 European Society of Cardiology Congress. The presentations include head to head Phase IV results for Leqvio in LDL C management. New analyses on bleeding risk for abelacimab in atrial fibrillation are also scheduled for the ESC 2026 program. These data may influence future treatment guidelines and physician use of Novartis cardiovascular therapies. Investors watching how large...
Simply Wall St. · Aug 20, 2026
홀더
NVS 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
7.3%
기관 보유 (유동주식)
7.3%
내부자 보유
0.0%
기관 수
1,812
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Fisher Asset Management, LLC | 15.52M | $2.36B | 0.8% | 11.8% | Jun 30, 2026 |
| Morgan Stanley | 8.73M | $1.33B | 0.4% | 2.3% | Jun 30, 2026 |
| Dimensional Fund Advisors LP | 8.12M | $1.23B | 0.4% | 0.1% | Jun 30, 2026 |
| Primecap Management Company | 6.59M | $1.00B | 0.3% | -12.9% | Jun 30, 2026 |
| LOOMIS SAYLES & CO L P | 5.24M | $796.69M | 0.3% | -3.4% | Jun 30, 2026 |
| Bank of America Corporation | 4.91M | $746.61M | 0.2% | -1.1% | Jun 30, 2026 |
| Franklin Resources, Inc. | 3.25M | $494.39M | 0.2% | -4.7% | Jun 30, 2026 |
| Blackrock Inc. | 3.05M | $463.48M | 0.1% | 3.3% | Jun 30, 2026 |
| Goldman Sachs Group Inc | 2.98M | $453.16M | 0.1% | -54.3% | Jun 30, 2026 |
| Northern Trust Corporation | 2.79M | $424.66M | 0.1% | 0.2% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.